Her2 Antibodies Market

HER2 Antibodies Market (Type of Treatment Drugs - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, and Everolimus) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

  • Rep Id : TMRGL7301
  • Published On : Aug 2017
  • No. of Pages : 112
  • Category : Healthcare

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview
      4.1. Introduction
      4.2. Overview
      4.3. Key Market Indicators
      4.4. Market Dynamics
              4.4.1. Drivers
              4.4.2. Restraints 
              4.4.3. Opportunities
              4.4.4. Trends
      4.5. Global HER2 Antibodies Market Analysis and Forecasts, 2015–2025
              4.5.1. Market Revenue Projections (US$ Mn)
      4.6. Porter’s Five Force Analysis
      4.7. Market Outlook

5. Global HER2 Antibodies Market, Analysis and Forecasts, By Type of Treatment Drugs
      5.1. Introduction & Definition
      5.2. Key Findings / Developments      
      5.3. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              5.3.1. Trastuzumab 
              5.3.2. Lapatinib 
              5.3.3. Ado-trastuzumab emtansine
              5.3.4. Pertuzumab 
              5.3.5. Everolimus 

6. Global HER2 Antibodies Market Analysis and Forecasts, By Region
      6.1. Key Findings
      6.2. Market Value Forecast by Region
              6.2.1. North America 
              6.2.2. Europe 
              6.2.3. Asia Pacific 
              6.2.4. Latin America 
              6.2.5. Middle East and Africa 
      6.3. Market Attractiveness by Country/Region

7. North America HER2 Antibodies Market, Analysis and Forecast
      7.1. Introduction
              7.1.1. Key Findings
              7.1.2. Policies and Regulations
              7.1.3. Key Trends
      7.2. Market Value Forecast by Country, 2015–2025
              7.2.1. U.S.
              7.2.2. Canada
      7.3. Market Attractiveness by Country      
      7.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              7.4.1. Trastuzumab 
              7.4.2. Lapatinib 
              7.4.3. Ado-trastuzumab emtansine
              7.4.4. Pertuzumab 
              7.4.5. Everolimus 
      7.5. Market Attractiveness by Type of Treatment Drugs

8. Europe HER2 Antibodies Market, Analysis and Forecast
      8.1. Introduction
              8.1.1. Key Findings
              8.1.2. Policies and Regulations
              8.1.3. Key Trends
      8.2. Market Value Forecast by Country, 2015–2025
              8.2.1. U.K.
              8.2.2. Germany
              8.2.3. France
              8.2.4. Italy
              8.2.5. Spain
              8.2.6. Rest of Europe
      8.3. Market Attractiveness by Country
      8.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              8.4.1. Trastuzumab 
              8.4.2. Lapatinib 
              8.4.3. Ado-trastuzumab emtansine
              8.4.4. Pertuzumab 
              8.4.5. Everolimus 
      8.5. Market Attractiveness by Type of Treatment Drugs

9. Asia Pacific HER2 Antibodies Market, Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
              9.1.2. Policies and Regulations
              9.1.3. Key Trends
      9.2. Market Value Forecast by Country, 2015–2025
              9.2.1. Japan
              9.2.2. China
              9.2.3. India
              9.2.4. Australia & New Zealand
              9.2.5. Rest of Asia Pacific
      9.3. Market Attractiveness by Country
      9.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              9.4.1. Trastuzumab 
              9.4.2. Lapatinib 
              9.4.3. Ado-trastuzumab emtansine
              9.4.4. Pertuzumab 
              9.4.5. Everolimus 
      9.5. Market Attractiveness by Type of Treatment Drugs

10. Latin America HER2 Antibodies Market, Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
              10.1.2. Policies and Regulations
              10.1.3. Key Trends
      10.2. Market Value Forecast by Country, 2015–2025
              10.2.1. Brazil
              10.2.2. Mexico
              10.2.3. Rest of LATAM
      10.3. Market Attractiveness by Country
      10.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              10.4.1. Trastuzumab 
              10.4.2. Lapatinib 
              10.4.3. Ado-trastuzumab emtansine
              10.4.4. Pertuzumab 
              10.4.5. Everolimus 
      10.5. Market Attractiveness by Type of Treatment Drugs

11. Middle East & Africa HER2 Antibodies Market, Analysis and Forecast
      11.1. Introduction
              11.1.1. Key Findings
              11.1.2. Policies and Regulations
              11.1.3. Key Trends
      11.2. Market Value Forecast by Country, 2015–2025
              11.2.1. Saudi Arabia
              11.2.2. South Africa
              11.2.3. Rest of MEA
      11.3. Market Attractiveness by Country
      11.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
              11.4.1. Trastuzumab 
              11.4.2. Lapatinib 
              11.4.3. Ado-trastuzumab emtansine
              11.4.4. Pertuzumab 
              11.4.5. Everolimus 
      11.5. Market Attractiveness by Type of Treatment Drugs

12. Pipeline Analysis
      12.1. Pipeline Snapshot for HER2 Antibodies Market

13. Competition Landscape
      13.1. Heat Map Analysis by Company (2016)
      13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
              13.2.1. Novartis AG
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.2. Pfizer, Inc. 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.3. Genentech Inc. (F. Hoffmann-La Roche Ltd.)
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.4. Abnova Corporation 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.5. InvivoGen 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.6. Celltrion, Inc. 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.7. Biocon Limited 
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 
              13.2.8. Bio-Techne (Novus Biologicals, LLC)
                         13.2.1.1. Company Overview
                         13.2.1.2. Business Overview
                         13.2.1.3. Financial Overview
                         13.2.1.4. SWOT Analysis
                         13.2.1.5. Strategic Overview 

List of Tables

Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025

List of Figures

Figure 01: HER2 Antibodies Market, by Type of Treatment Drugs, Market Size (US$ Mn), 2016 (A)
Figure 02: HER2 antibodies market revenue (%), by top three drugs, 2016 (A)
Figure 03: Executive Summary (2/3)
Figure 04: Executive Summary (3/3)
Figure 05: Opportunity Map, 2017
Figure 06: Key Industry Developments
Figure 07: Drivers and Restraints Snapshot (1/1)
Figure 08: Global HER2 Antibodies Market Size (US$ Mn) Forecast, 2015–2025
Figure 09: Porter’s Five Forces Analysis (1/2)
Figure 10: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs (2016)
Figure 11: Global HER2 Antibodies Market Value Share, by Region (2016)
Figure 12: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 13: Global HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 14: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Trastuzumab, 2015–2025
Figure 15: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lapatinib, 2015–2025
Figure 16: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Ado-trastuzumab Emtansine, 2015–2025
Figure 17: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pertuzumab, 2015–2025
Figure 18: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Everolimus, 2015–2025
Figure 19: Global Market Scenario
Figure 20: Global HER2 Antibodies Market Value Share, by Region, 2017 and 2025 
Figure 21: Global HER2 Antibodies Market Attractiveness, by Region, 2017–2025
Figure 22: North America HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 23: North America HER2 Antibodies Market Attractiveness Analysis, by Country
Figure 24: North America HER2 Antibodies Market Value Share Analysis, by Country, 2017 and 2025
Figure 25: North America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 26: North America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 27: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 28: Europe HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 29: Europe Market Value Share Analysis, by Country, 2017 and 2025
Figure 30: Europe HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 31: Europe HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 32: Asia Pacific HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 33: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country. 2017-2025
Figure 34: Asia Pacific Market Value Share Analysis, by Country, 2017 and 2025
Figure 35: Asia Pacific HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 36: Asia Pacific HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 37: Latin America HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 38: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 39: Latin America Market Value Share Analysis, by Country, 2017 and 2025
Figure 40: Latin America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 41: Latin America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 42: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) and
Figure 43: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 44: Middle East & Africa Market Value Share Analysis, by Country, 2017 and 2025
Figure 45: Middle East & Africa HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 46: Middle East & Africa HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 47: Pipeline Snapshot of HER2 Antibodies Market (1/2)
Figure 48: Pipeline Snapshot of HER2 Antibodies Market (2/2)
Figure 49: Global HER2 Antibodies Market Heat Map Analysis by Company (2016)
Figure 50: Novartis AG Breakdown of Net Sales, by Region (2016)
Figure 51: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 52: Pfizer, Inc. Breakdown of Net Sales, by Region (2016)
Figure 53: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 54: Genentech Inc. Breakdown of Net Sales, by Segment, 2016
Figure 55: Genentech Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 56: Abnova Corporation Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 57: Celltrion, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2015
Figure 58: Biocon Limited Breakdown of Net Sales, by Business Segments, 2016
Figure 59: Biocon Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 60: Bio-Techne Breakdown of Net Sales, by Business Segment, 2016
Figure 61: Bio-Techne Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016

.